XNAS · Healthcare · Biotechnology
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.78 | -1.77 | -126.92% | $1.0M | ❌ Miss | +0.00% | +8.29% | — |
| 2026-05-13 | Q1 2026 | -1.54 | -1.46 | +5.19% | $0 | ✅ Beat | +2.30% | -1.86% | -0.65% |
| 2026-03-16 |
| Q4 2025 |
| — |
| -4.54 |
| — |
| $0 |
| — |
| -1.62% |
| -11.19% |
| -9.38% |
| 2025-11-12 | Q3 2025 | -0.98 | -1.22 | -24.49% | $0 | ❌ Miss | — | — | — |
| 2025-08-12 | Q2 2025 | -1.04 | -1.25 | -20.19% | $0 | ❌ Miss | -2.65% | -0.31% | +26.86% |
Showing last 5 quarters.